Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Receptor, ErbB-2

abstract

  • Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

publication date

  • March 15, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJM200103153441101

PubMed ID

  • 11248153

Additional Document Info

start page

  • 783

end page

  • 92

volume

  • 344

number

  • 11